REG - Inspiration Health - UK neonatal division wins NHS framework agreement

Inspiration HealthcareAnnouncement

Today 07:00

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20260305:nRSE3861Va&default-theme=true

RNS Number : 3861V  Inspiration Healthcare Group PLC  05 March 2026

Inspiration Healthcare Group plc

("Inspiration Healthcare", the "Company" or the "Group")

 

UK neonatal division secures renewed four-year NHS framework agreement

No. 1 position in neonatal ventilator suppliers to England & Wales NHS

 

Inspiration Healthcare Group plc (AIM: IHC), the global medical technology
company pioneering best-in-class, specialist neonatal intensive care medical
devices, announces that it has been re-appointed by the NHS supply chain as an
approved supplier for its respiratory care units for newborns under a new
four-year framework agreement covering England and Wales. In addition, the
Company has been ranked as the number one neonatal ventilator supplier* for
the 2025/26 period under the NHS framework in England and Wales.

 

Strategic and financial impact

 

·      Secures framework position for four years, providing enhanced
medium-term revenue visibility within the UK market

·      Reinforces Inspiration Healthcare's market-leading position in
neonatal ventilation across England and Wales

·      Supports ongoing capital equipment sales, associated consumables
and service revenue streams

·      Strengthens competitive positioning in future procurement cycle

 

The renewed framework appointment ensures continued streamlined access for NHS
Trusts to Inspiration Healthcare's portfolio of neonatal respiratory and
critical care solutions for vulnerable patients. Framework inclusion supports
procurement efficiency, regulatory compliance and value-based purchasing
across the healthcare system, enabling NHS Trusts to obtain equipment through
a compliant and pre-approved route. The four-year term provides enhanced
visibility of opportunity within the NHS procurement cycle and strengthens the
Company's strategic positioning in the UK neonatal care market.

 

Raffi Stepanian, CEO of Inspiration Healthcare, said: "The renewal of this
framework and our ranking within the NHS reflects our continued commitment to
medical excellence, innovation and the advancement of clinical outcomes within
neonatal intensive care environments. Our neonatal ventilator systems are
designed to deliver precise, reliable respiratory support for premature and
critically ill newborns, and we are consistently investing in product
development, clinical training and service support to ensure that clinicians
are equipped to support safe and effective care for vulnerable patients. We
remain focused on converting this strategic positioning into further market
share gains and long-term shareholder value."

 

*The number one ranking reflects the Company's leading market share position
within the NHS supply chain neonatal ventilator category for the designated
period.

 

For further information, please contact:

 

 Inspiration Healthcare Group plc                                                               Tel: +44 (0)330
                                                                175 0000
 Raffi Stepanian, Chief Executive Officer
 Alan Olby, Chief Financial Officer

 Panmure Liberum (Nominated Adviser & Broker)                                                                                                                     Tel: +44 (0)20
                                                                                                                                  3100 2000
 Will Goode
 Emma Earl
 Mark Rogers

 Cavendish Capital Markets (Joint Broker)                                             Tel: + 44 (0)20 7220 0500
 Giles Balleny / Joe Smith
 Nigel Birks
 Harriet Ward

 Walbrook PR Ltd (Media & IR)      Tel: +44 (0)20 7933 8780 or inspirationhealthcare@walbrookpr.com
 Anna Dunphy                                                    Mob: +44 (0) 7876 741 001
 Rachel Broad                                                   Mob: +44 (0) 7747 515 393

 

About Inspiration Healthcare

 

Inspiration Healthcare (AIM: IHC) designs, manufactures and markets
pioneering medical technology. Based in the UK, the Company specialises in
neonatal intensive care medical devices, which are addressing a critical need
to help to save the lives and improve the outcomes of patients, starting with
the very first breaths of life.

 

The Company has a broad portfolio of its own products and complementary
distributed products, for use in neonatal intensive care designed to support
even the most premature babies throughout their hospital stay. Its own branded
products range from highly sophisticated capital equipment such as ventilators
for life support through to single-use disposables.

 

The Company sells its products directly to hospitals and healthcare providers
in the UK and Ireland, where it also distributes a range of advanced medical
technologies for infusion therapy.  In the rest of the world the Company has
an established network of distribution partners around the world giving access
to more than 75 countries.

 

The Company operates in the UK from its world-class Manufacturing and
Technology Centre in Croydon, South London and in the USA from its facility in
Melbourne, Florida.

 

Further information on Inspiration Healthcare can be found
at www.inspirationhealthcaregroup.com
(http://www.inspirationhealthcaregroup.com)

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  AGRUPUWCWUPQGMC



            Copyright 2019 Regulatory News Service, all rights reserved